ELDEPRYL

This brand name is authorized in Australia, Finland, Ireland, Malta, United Kingdom, South Africa

Active ingredients

The drug ELDEPRYL contains one active pharmaceutical ingredient (API):

1 Selegiline UNII 6W731X367Q - SELEGILINE HYDROCHLORIDE

Selegiline is a selective MAO-B-inhibitor which prevents dopamine breakdown in the brain. It also inhibits the reuptake of dopamine at the presynaptic dopamine receptor. These effects potentiate dopaminergic function in the brain and help to even out and prolong the effect of exogenous and endogenous dopamine. Thus, selegiline potentiates and prolongs the effect of levodopa in the treatment of parkinsonism. Read about Selegiline

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ELDEPRYL Tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N04BD01	Selegiline	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BD Monoamine oxidase B inhibitors
Discover more medicines within N04BD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 1973W
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 476192, 534024
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 209809, 209811
Country: IE	Health Products Regulatory Authority	Identifier(s): 22805, 22853
Country: MT	Medicines Authority	Identifier(s): AA565/24902
Country: ZA	Health Products Regulatory Authority	Identifier(s): T/5.4.1/95